Uncontrolled Hypertension Clinical Trial
— RICH LIFEOfficial title:
Comparative Effectiveness of Health System vs. Multilevel Interventions to Reduce Hypertension Disparities
Verified date | June 2022 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The RICH LIFE Project is a two-armed, cluster-randomized trial, comparing the effectiveness of an enhanced standard of care arm, "Standard of Care Plus" (SCP), to a multi-level intervention, "Collaborative Care/Stepped Care" (CC/SC), in improving blood pressure control, patient activation and reducing disparities in blood pressure control among 1,890 adult patients with uncontrolled hypertension and cardiovascular disease risk factors at thirty primary care practices in Maryland and Pennsylvania. Fifteen practices randomized to the SCP arm receive standardized blood pressure measurement training, and audit and feedback of blood pressure control rates at the practice provider level. Fifteen practices in the CC/SC arm receive all the SCP interventions plus the implementation of the collaborative care model with additional stepped-care components of community health worker referrals and subspecialist curbside consults and an on-going virtual workshop for organizational leaders in quality improvement and disparities reduction. The primary clinical outcomes are the percent of patients with blood pressure <140/90 mm Hg and change from baseline in mean systolic blood pressure at 12 months. The primary patient reported outcome is change from baseline in self-reported patient activation at 12 months.
Status | Completed |
Enrollment | 1820 |
Est. completion date | February 28, 2022 |
Est. primary completion date | February 28, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years to 100 Years |
Eligibility | Inclusion Criteria: 1. Adult patients (=21 years of age) obtaining primary care from a provider at a participating practice 2. A diagnosis of hypertension or SBP=140mmHg or DBP=90mmHg twice in the past year or on antihypertensive medications plus at least one of the following CVD risk factors: - Diabetes mellitus (fasting blood sugar> 125mg/dl or hemoglobin A1c>6.5 or on a hypoglycemic medication); - Dyslipidemia (LDL >130 mg/dl, HDL<40 or total cholesterol >200 or on a lipid lowering agent); - Coronary heart disease - Current tobacco smokers - Depression by International Classification of Disease, 9th edition (ICD-9), codes or Patient Health Questionnaire (PHQ) score >9 Exclusion Criteria: 1. Cardiovascular event (unstable angina, myocardial infarction) within the past 6 months 2. Serious medical condition which either limits life expectancy or requires active management (e.g., certain cancers) 3. Condition which interferes with outcome measurement (e.g., dialysis) 4. Pregnant or planning a pregnancy during study period. Nursing mothers would need approval from physician. 5. Alcohol or substance use disorder if not sober/abstinent for =30 days 6. Planning to leave clinic within 6 months or move out of geographic area within 18 months 7. Individuals with cognitive impairment or other condition which makes them unable to participate in the intervention 8. Participating in another lifestyle modification, weight reduction, or treatment trial |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins University School of Medicine | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University | National Heart, Lung, and Blood Institute (NHLBI), Patient-Centered Outcomes Research Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Controlled Blood Pressure | Number of participants with Controlled Blood Pressure (<140/90 mm Hg). | 12 months | |
Primary | Patient Activation Measure (PAM-13) | The Patient Activation Measure assesses knowledge, skills, and confidence in the management of one's health. It is comprised of 13 items and each item is on a 1-5 scale. Insignia health scores on a standardized overall score of 0-100 where higher scores indicate a better outcome. | Baseline, 12 months | |
Secondary | Mean Systolic Blood Pressure | Mean Systolic Blood Pressure in mm Hg at baseline and 12 months. | Baseline, 12 months | |
Secondary | Mean Diastolic Blood Pressure | Mean Diastolic Blood Pressure in mm Hg at baseline and 12 months. | Baseline, 12 months | |
Secondary | Change in Global Framingham Risk Score | Clinical Outcome | Baseline, 12, 24 months | |
Secondary | Change in Mean Total Cholesterol (mg/dL) | Clinical Outcome | Baseline, 12, 24 months | |
Secondary | Change in Mean LDL-C (mg/dL) | Clinical Outcome | Baseline, 12, 24 months | |
Secondary | Change in Mean HDL (mg/dL) | Clinical Outcome | Baseline, 12, 24 months | |
Secondary | % With Controlled Total Cholesterol | Clinical Outcome | Baseline | |
Secondary | % With Controlled Total Cholesterol | Clinical Outcome | 12 months | |
Secondary | % With Controlled Total Cholesterol | Clinical Outcome | 24 months | |
Secondary | Change in Mean Glycosylated Hemoglobin (Hemoglobin A1c) | Clinical Outcome | Baseline, 12, 24 months | |
Secondary | % With Hemoglobin A1c< 7.0 | Clinical Outcome | Baseline | |
Secondary | % With Hemoglobin A1c< 7.0 | Clinical Outcome | 12 months | |
Secondary | % With Hemoglobin A1c< 7.0 | Clinical Outcome | 24 months | |
Secondary | Change in Patient Assessment of Care for Chronic Conditions (PACIC-Plus) | Patient Reported Outcome | Baseline, 12, 24 months | |
Secondary | % With BP <140/90 mmHg | Clinical Outcome | 24 months | |
Secondary | % With BP <130/80 mmHg | Clinical Outcome | 12 months | |
Secondary | % With BP <130/80 mmHg | Clinical Outcome | 24 months | |
Secondary | % With BP <120/80 mmHg | Clinical Outcome | 12 months | |
Secondary | % With BP <120/80 mmHg | Clinical Outcome | 24 months | |
Secondary | Change in Medication Adherence 4-Item Scale | Patient Reported Outcome | Baseline, 12, 24 months | |
Secondary | Change in Depressive Symptoms Patient Health Questionnaire (PHQ) 8 Score | Patient Reported Outcome | Baseline 12, 24 months | |
Secondary | Change in Patient Ratings of Trust | Patient Reported Outcome | Baseline, 12, 24 months | |
Secondary | Change in Hypertension Knowledge and Attitudes | Patient Reported Outcome | Baseline, 12, 24 months | |
Secondary | Change in Health Related Quality of Life (PROMIS Global Scale) | Patient Reported Outcome | Baseline, 12, 24 months | |
Secondary | Change in Patient Attainment of Self-Defined Goals | Patient Reported Outcome | Baseline, 12, 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01939392 -
Rapid Renal Sympathetic Denervation for Resistant Hypertension II
|
Phase 2/Phase 3 | |
Terminated |
NCT01966952 -
Evaluation of Safety Mechanisms of Renal Radioablation(RSRA)for Uncontrolled Hypertension
|
N/A | |
Completed |
NCT01699529 -
Multi-electrode Radiofrequency Renal Denervation System Feasibility Study
|
N/A | |
Completed |
NCT01418261 -
SYMPLICITY HTN-3 Renal Denervation in Patients With Uncontrolled Hypertension
|
N/A | |
Completed |
NCT01635998 -
Adjunctive Renal Denervation in the Treatment of Atrial Fibrillation
|
N/A | |
Completed |
NCT04809519 -
Integrative Nursing Based Multimodal Interventions for Uncontrolled Hypertensives
|
N/A | |
Completed |
NCT01996033 -
EnligHTN German Observational Study of Renal Denervation for Uncontrolled Hypertension
|
||
Terminated |
NCT01628198 -
Impact of Renal SympAthetic DenerVation on Chronic HypErtension
|
N/A | |
Recruiting |
NCT03221114 -
Positive Psychology Intervention for Spanish-speaking Hispanic/Latino Adults at Risk for Cardiovascular Disease
|
N/A | |
Completed |
NCT04248530 -
DENEX Renal Denervation in Patients With Uncontrolled Hypertension: Safety Study
|
N/A | |
Recruiting |
NCT06034743 -
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
|
Phase 3 | |
Completed |
NCT02006758 -
Observational Study of the EnligHTN Renal Denervation System in Europe
|
||
Active, not recruiting |
NCT03209154 -
An Interventional Multidisciplinary Approach to Individualize Blood Pressure Treatment
|
N/A | |
Withdrawn |
NCT05352425 -
Effect of the MobiusHD® in Renal Hemodialysis Subjects With Uncontrolled Hypertension
|
N/A | |
Completed |
NCT05395403 -
Use of Automated Office Blood Pressure Monitoring
|
N/A | |
Recruiting |
NCT05732727 -
Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT02418091 -
Integrated Population Program for Diabetic Kidney Disease
|
N/A | |
Not yet recruiting |
NCT05234788 -
Renal Artery DenervatIon Using Radial accesS in Uncontrolled HyperTensioN
|
N/A | |
Completed |
NCT00888433 -
Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)
|
N/A | |
Recruiting |
NCT05460169 -
Renal Denervation in ADPKD- RDN-ADPKD Study
|
N/A |